Larimar Therapeutics/$LRMR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Larimar Therapeutics

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Ticker

$LRMR

Sector

Health
Primary listing

Employees

65

LRMR Metrics

BasicAdvanced
$313M
-
-$1.49
0.91
-

What the Analysts think about LRMR

Analyst ratings (Buy, Hold, Sell) for Larimar Therapeutics stock.

Bulls say / Bears say

The FDA has signaled support for using skin frataxin concentrations as a surrogate endpoint and provided clear guidance for the nomlabofusp BLA, enabling the company to target accelerated approval by year-end 2025 and derisking the regulatory pathway.
With $157.5 million in cash and marketable securities as of March 31, 2025, and no debt, Larimar is well-capitalized to fund its Phase 3 program and BLA submission through mid-2026 without immediate dilution.
Initiation of coverage by Truist Securities with a Buy rating and an average price target of $21.93 (491% upside), combined with a consensus Buy rating and average target of ~$20.13 from 11 analysts, reflects strong institutional and broker-dealer confidence in Larimar’s long-term prospects
Larimar’s quarterly cash burn has nearly doubled year-over-year, with R&D expenses rising to $26.6 million in Q1 2025, and cash runway extending only into Q2 2026, suggesting the company may need to raise additional capital and dilute shareholders sooner than anticipated.
Key clinical catalysts remain distant, as global Phase 3 initiation is not expected until mid-2025 and topline data from the open-label extension and adolescent PK cohort won’t be available until September 2025, prolonging the period without material news.
Larimar continues to generate no revenue and has posted consecutive EPS misses (Q4 2024 EPS of -$0.45 vs. estimate -$0.29 and Q1 2025 EPS of -$0.46), underscoring its unprofitable profile and reliance on future clinical success
Data summarised monthly by Lightyear AI. Last updated on 22 Jul 2025.

LRMR Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

LRMR Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LRMR

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs